Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma

Carlo Scarabelli, Angelo Gallo, Silvia Franceschi, Elio Campagnutta, Giovanni De Piero, Giorgio Giorda, Maria Caterina Visentin, Antonino Carbone

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The impact of radical bowel resection with multiple organ resection on the survival if patients with advanced ovarian carcinoma has not been well defined. The authors investigated whether primary cytoreductive surgery including rectosigmoid colon resection would affect the recurrence free interval and survival of these patients. METHODS. Between April 1990 and April 1997, 66 previously untreated Stage IIIC-IV ovarian carcinoma patients with macroscopic involvement of the rectosigmoid colon were enrolled. All patients underwent cytoreductive surgery with rectosigmoid colon resection to remove residual tumor less than 2 cm in greatest dimension and received 6 cycles of cisplatin-based postoperative chemotherapy. RESULTS. The median follow-up was 26 months (range, 7-104 months). In multivariate analysis, residual disease and depth of tumor infiltration of the bowel wall were independently associated with overall survival and recurrence free interval. Disease stage was independently associated only with overall survival. Residual tumor was the most strongly predictive factor for recurrence or death. The 2-year estimated survival rates according to the amount of residual tumor were 100% for 24 patients with no macroscopic residual disease and 77.3% for 28 patients with residual disease less than 1 cm. None of the 14 patients with residual disease larger than 1 cm were alive 2-years after operation. Overall, 48 patients (72.7%) developed disease recurrence: 43 (65.1%) in the abdomen, 19 (29.8%) in the liver, and 3 (4.5%) in the pelvis. CONCLUSIONS. The current findings suggest that cytoreductive surgery with rectosigmoid colon resection should be considered for ovarian carcinoma patients with bulky pelvic disease to help ensure that they are left with no residual disease after debulking surgery.

Original languageEnglish
Pages (from-to)389-397
Number of pages9
JournalCancer
Volume88
Issue number2
DOIs
Publication statusPublished - Jan 15 2000

Fingerprint

Colon
Carcinoma
Residual Neoplasm
Recurrence
Survival
Pelvis
Abdomen
Cisplatin
Multivariate Analysis
Survival Rate
Drug Therapy
Liver
Neoplasms

Keywords

  • Bowel surgery
  • Cytoreductive surgery
  • Ovarian carcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. / Scarabelli, Carlo; Gallo, Angelo; Franceschi, Silvia; Campagnutta, Elio; De Piero, Giovanni; Giorda, Giorgio; Visentin, Maria Caterina; Carbone, Antonino.

In: Cancer, Vol. 88, No. 2, 15.01.2000, p. 389-397.

Research output: Contribution to journalArticle

Scarabelli, Carlo ; Gallo, Angelo ; Franceschi, Silvia ; Campagnutta, Elio ; De Piero, Giovanni ; Giorda, Giorgio ; Visentin, Maria Caterina ; Carbone, Antonino. / Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. In: Cancer. 2000 ; Vol. 88, No. 2. pp. 389-397.
@article{66b3128b6e094009aca22b296d93e3a6,
title = "Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma",
abstract = "BACKGROUND. The impact of radical bowel resection with multiple organ resection on the survival if patients with advanced ovarian carcinoma has not been well defined. The authors investigated whether primary cytoreductive surgery including rectosigmoid colon resection would affect the recurrence free interval and survival of these patients. METHODS. Between April 1990 and April 1997, 66 previously untreated Stage IIIC-IV ovarian carcinoma patients with macroscopic involvement of the rectosigmoid colon were enrolled. All patients underwent cytoreductive surgery with rectosigmoid colon resection to remove residual tumor less than 2 cm in greatest dimension and received 6 cycles of cisplatin-based postoperative chemotherapy. RESULTS. The median follow-up was 26 months (range, 7-104 months). In multivariate analysis, residual disease and depth of tumor infiltration of the bowel wall were independently associated with overall survival and recurrence free interval. Disease stage was independently associated only with overall survival. Residual tumor was the most strongly predictive factor for recurrence or death. The 2-year estimated survival rates according to the amount of residual tumor were 100{\%} for 24 patients with no macroscopic residual disease and 77.3{\%} for 28 patients with residual disease less than 1 cm. None of the 14 patients with residual disease larger than 1 cm were alive 2-years after operation. Overall, 48 patients (72.7{\%}) developed disease recurrence: 43 (65.1{\%}) in the abdomen, 19 (29.8{\%}) in the liver, and 3 (4.5{\%}) in the pelvis. CONCLUSIONS. The current findings suggest that cytoreductive surgery with rectosigmoid colon resection should be considered for ovarian carcinoma patients with bulky pelvic disease to help ensure that they are left with no residual disease after debulking surgery.",
keywords = "Bowel surgery, Cytoreductive surgery, Ovarian carcinoma, Survival",
author = "Carlo Scarabelli and Angelo Gallo and Silvia Franceschi and Elio Campagnutta and {De Piero}, Giovanni and Giorgio Giorda and Visentin, {Maria Caterina} and Antonino Carbone",
year = "2000",
month = "1",
day = "15",
doi = "10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W",
language = "English",
volume = "88",
pages = "389--397",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma

AU - Scarabelli, Carlo

AU - Gallo, Angelo

AU - Franceschi, Silvia

AU - Campagnutta, Elio

AU - De Piero, Giovanni

AU - Giorda, Giorgio

AU - Visentin, Maria Caterina

AU - Carbone, Antonino

PY - 2000/1/15

Y1 - 2000/1/15

N2 - BACKGROUND. The impact of radical bowel resection with multiple organ resection on the survival if patients with advanced ovarian carcinoma has not been well defined. The authors investigated whether primary cytoreductive surgery including rectosigmoid colon resection would affect the recurrence free interval and survival of these patients. METHODS. Between April 1990 and April 1997, 66 previously untreated Stage IIIC-IV ovarian carcinoma patients with macroscopic involvement of the rectosigmoid colon were enrolled. All patients underwent cytoreductive surgery with rectosigmoid colon resection to remove residual tumor less than 2 cm in greatest dimension and received 6 cycles of cisplatin-based postoperative chemotherapy. RESULTS. The median follow-up was 26 months (range, 7-104 months). In multivariate analysis, residual disease and depth of tumor infiltration of the bowel wall were independently associated with overall survival and recurrence free interval. Disease stage was independently associated only with overall survival. Residual tumor was the most strongly predictive factor for recurrence or death. The 2-year estimated survival rates according to the amount of residual tumor were 100% for 24 patients with no macroscopic residual disease and 77.3% for 28 patients with residual disease less than 1 cm. None of the 14 patients with residual disease larger than 1 cm were alive 2-years after operation. Overall, 48 patients (72.7%) developed disease recurrence: 43 (65.1%) in the abdomen, 19 (29.8%) in the liver, and 3 (4.5%) in the pelvis. CONCLUSIONS. The current findings suggest that cytoreductive surgery with rectosigmoid colon resection should be considered for ovarian carcinoma patients with bulky pelvic disease to help ensure that they are left with no residual disease after debulking surgery.

AB - BACKGROUND. The impact of radical bowel resection with multiple organ resection on the survival if patients with advanced ovarian carcinoma has not been well defined. The authors investigated whether primary cytoreductive surgery including rectosigmoid colon resection would affect the recurrence free interval and survival of these patients. METHODS. Between April 1990 and April 1997, 66 previously untreated Stage IIIC-IV ovarian carcinoma patients with macroscopic involvement of the rectosigmoid colon were enrolled. All patients underwent cytoreductive surgery with rectosigmoid colon resection to remove residual tumor less than 2 cm in greatest dimension and received 6 cycles of cisplatin-based postoperative chemotherapy. RESULTS. The median follow-up was 26 months (range, 7-104 months). In multivariate analysis, residual disease and depth of tumor infiltration of the bowel wall were independently associated with overall survival and recurrence free interval. Disease stage was independently associated only with overall survival. Residual tumor was the most strongly predictive factor for recurrence or death. The 2-year estimated survival rates according to the amount of residual tumor were 100% for 24 patients with no macroscopic residual disease and 77.3% for 28 patients with residual disease less than 1 cm. None of the 14 patients with residual disease larger than 1 cm were alive 2-years after operation. Overall, 48 patients (72.7%) developed disease recurrence: 43 (65.1%) in the abdomen, 19 (29.8%) in the liver, and 3 (4.5%) in the pelvis. CONCLUSIONS. The current findings suggest that cytoreductive surgery with rectosigmoid colon resection should be considered for ovarian carcinoma patients with bulky pelvic disease to help ensure that they are left with no residual disease after debulking surgery.

KW - Bowel surgery

KW - Cytoreductive surgery

KW - Ovarian carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034650684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034650684&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W

DO - 10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W

M3 - Article

C2 - 10640973

AN - SCOPUS:0034650684

VL - 88

SP - 389

EP - 397

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -